Genscript rebounds on HKEX with staunch defense of Legend Biotech's CAR-T data integrity
After a scathing short report triggered a landslide for Genscript’s stock and forced it to halt trading, the company has managed to salvage some of that loss with a response issued Friday morning.
In the statement, Genscript kicked back against the allegations leveled against Nanjing Legend Biotech, its subsidiary developing a J&J-partnered CAR-T therapy. Their Hong Kong-listed shares has risen almost 16% from the lowest point Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.